# Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma

> **NCT05117008** · PHASE2 · TERMINATED · sponsor: **Medical College of Wisconsin** · enrollment: 1 (actual)

## Conditions studied

- Refractory Multiple Myeloma
- Relapse Multiple Myeloma

## Interventions

- **DRUG:** Belantamab mafodotin

## Key facts

- **NCT ID:** NCT05117008
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-07-19
- **Primary completion:** 2024-01-15
- **Final completion:** 2024-01-15
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Low enrollment.
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05117008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05117008, "Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05117008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*